AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32773594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 34976333 — intervention group
Group type: EXPERIMENTAL
Intervention: X-ray examination results
Number of subjects: 152000
Study 34976333 — intervention group
Group type: EXPERIMENTAL
Intervention: CT examination results
Number of subjects: 152000
Study 32102119 — intervention group
Group type: EXPERIMENTAL
Intervention: Reablement group
Number of subjects: 114
Study 32102119 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminding group
Number of subjects: 114
Study 32102119 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study 35701794 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-sitting position
Number of subjects: 116
Study 35701794 — intervention group
Group type: COMPARATOR
Intervention: Lateral position
Number of subjects: 116
Study 33789722 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BTX) injection into the cricopharyngeal muscle
Number of subjects: 44
Study 33789722 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 44
Study 32214382 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervicovaginal microbiome characteristics (specifically Lactobacillus iners)
Number of subjects: 273
Study 32214382 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervicovaginal microbiome characteristics (specifically Gardnerella)
Number of subjects: 273
Study 32214382 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased microbial Shannon diversity at Visit 2 (V2)
Number of subjects: 273
Study 32214382 — intervention group
Group type: EXPERIMENTAL
Intervention: V1 genus Lactobacillus
Number of subjects: 273
Study 32214382 — intervention group
Group type: EXPERIMENTAL
Intervention: V1 fungal diversity
Number of subjects: 273
Study 32214382 — intervention group
Group type: EXPERIMENTAL
Intervention: V1 functional Cell Motility pathway
Number of subjects: 273
Study 32214382 — intervention group
Group type: EXPERIMENTAL
Intervention: V2 bacterial diversity
Number of subjects: 273
Study 34651517 — intervention group
Group type: COMPARATOR
Intervention: PAR group (physical activity recommendation from WHO)
Number of subjects: 89
Study 34651517 — intervention group
Group type: COMPARATOR
Intervention: HIIT group (high-intensity interval training)
Number of subjects: 89
Study 34651517 — intervention group
Group type: COMPARATOR
Intervention: HIIT + EMS group (HIIT adding whole-body electromyostimulation training)
Number of subjects: 89
Study 33671310 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape Seed Extract (GSEe) 300 mg/day for 16 weeks
Number of subjects: 0
Study 33671310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33671310 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape Seed Extract (GSEe)
Number of subjects: 0
Study 34658152 — intervention group
Group type: EXPERIMENTAL
Intervention: Early childhood intervention (Melbourne INFANT program)
Number of subjects: 542
Study 34658152 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 542
Study 33160804 — intervention group
Group type: EXPERIMENTAL
Intervention: hipEOS (3D)
Number of subjects: 51
Study 33160804 — intervention group
Group type: COMPARATOR
Intervention: TraumaCad (2D)
Number of subjects: 51
Study 32745202 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (LIRA)
Number of subjects: 45
Study 32745202 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin (CANA)
Number of subjects: 45
Study 32745202 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide plus Canagliflozin (CANA/LIRA)
Number of subjects: 45
Study 32745202 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 45
Study 35385522 — intervention group
Group type: EXPERIMENTAL
Intervention: PAPR equipped with a cooling device
Number of subjects: 10
Study 35385522 — intervention group
Group type: COMPARATOR
Intervention: PAPR
Number of subjects: 10
Study 35385522 — intervention group
Group type: COMPARATOR
Intervention: Replaceable particulate respirator
Number of subjects: 10
Study 32814753 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotics (partially hydrolyzed guar gum) for four weeks
Number of subjects: 15
Study 32814753 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotics (partially hydrolyzed guar gum)
Number of subjects: 15
Study 35468322 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 117
Study 35468322 — intervention group
Group type: COMPARATOR
Intervention: Semaglutide 1 mg
Number of subjects: 117
Study 35468322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 32440938 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine (Lido/Epi)
Number of subjects: 0
Study 32440938 — intervention group
Group type: COMPARATOR
Intervention: 3% prilocaine with 0.03 IU/mL felypressin (Prilo/Fely)
Number of subjects: 0
Study 36138482 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding Your Baby (UYB)
Number of subjects: 1130
Study 36138482 — intervention group
Group type: COMPARATOR
Intervention: Care As Usual (CAU)
Number of subjects: 1130
Study 33616687 — intervention group
Group type: EXPERIMENTAL
Intervention: Incongruent Stroop task (iSTG)
Number of subjects: 42
Study 33616687 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent Stroop task (cSTG)
Number of subjects: 42
Study 33616687 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 42
Study 32745768 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee A (787 mg CGAs/day)
Number of subjects: 0
Study 32745768 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee B (407 mg CGAs/day)
Number of subjects: 0
Study 32745768 — intervention group
Group type: COMPARATOR
Intervention: Phenolic acids and CGAs in vitro
Number of subjects: 0
Study 35938207 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 0.5/NETA 0.1
Number of subjects: 107
Study 35938207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 32977025 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency transcranial magnetic stimulation (HF rTMS)
Number of subjects: 46
Study 32977025 — intervention group
Group type: COMPARATOR
Intervention: Sham control (not explicitly detailed)
Number of subjects: 46
Study 36308079 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 20 mg·kg‐1
Number of subjects: 30
Study 36308079 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 30
Study 33662244 — intervention group
Group type: EXPERIMENTAL
Intervention: MI Varnish®
Number of subjects: 44
Study 33662244 — intervention group
Group type: COMPARATOR
Intervention: Duraphat Varnish®
Number of subjects: 44
Study 32289297 — intervention group
Group type: EXPERIMENTAL
Intervention: Various LVAD interventions across major clinical trials
Number of subjects: 0
Study 32289297 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized stroke definitions and subtypes
Number of subjects: 0
Study 32289297 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of neurologists in study design
Number of subjects: 0
Study 32289297 — intervention group
Group type: EXPERIMENTAL
Intervention: Thorough evaluations of stroke etiology using multimodality techniques
Number of subjects: 0
Study 32289297 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoption of the National Institutes of Health Stroke Scale
Number of subjects: 0
Study 34275577 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired Associated Stimulation (PAS) with bilateral stimulation position
Number of subjects: 120
Study 34275577 — intervention group
Group type: COMPARATOR
Intervention: Paired Associated Stimulation (PAS) with ipsilesional stimulation position
Number of subjects: 120
Study 34275577 — intervention group
Group type: COMPARATOR
Intervention: Paired Associated Stimulation (PAS) with contralesional stimulation position
Number of subjects: 120
Study 32115349 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 1512
Study 32115349 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 1512
Study 33302802 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 ml sea buckthorn puree for 90 days
Number of subjects: 111
Study 33302802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 33626904 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (early use at day 0 to 3 for TIA, day 3 to 5 for small AIS, day 7 to 9 for medium AIS)
Number of subjects: 0
Study 33626904 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (early use)
Number of subjects: 0
Study 33626904 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (later use at 1 week post-TIA or 2 weeks post-AIS)
Number of subjects: 0
Study 33626904 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (later use)
Number of subjects: 0
Study 32376110 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) hepatitis A vaccine
Number of subjects: 78
Study 32376110 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) hepatitis A vaccine
Number of subjects: 78
Study 32376110 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events in SC group
Number of subjects: 78
Study 32376110 — intervention group
Group type: COMPARATOR
Intervention: Adverse events in IM group
Number of subjects: 78
Study 32376110 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for clotting factor concentrates due to adverse events in SC group
Number of subjects: 78
Study 32376110 — intervention group
Group type: COMPARATOR
Intervention: Need for clotting factor concentrates due to adverse events in IM group
Number of subjects: 78
Study 35399854 — intervention group
Group type: EXPERIMENTAL
Intervention: CEUS combined with enhanced MR scanning
Number of subjects: 90
Study 35399854 — intervention group
Group type: COMPARATOR
Intervention: CEUS
Number of subjects: 90
Study 33621009 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 75mg BID
Number of subjects: 256
Study 33621009 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin 5mg orally once daily
Number of subjects: 256
Study 33621009 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pregabalin and solifenacin
Number of subjects: 256
Study 33621009 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drugs)
Number of subjects: 256
Study 35027418 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative Coronary Angiography (QCA)
Number of subjects: 1528
Study 35027418 — intervention group
Group type: COMPARATOR
Intervention: Intravascular Ultrasound (IVUS)
Number of subjects: 1528
Study 34215498 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 100
Study 34215498 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemoradiotherapy (CHRT)
Number of subjects: 100
Study 32614232 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT) measurement during psychotherapy
Number of subjects: 0
Study 32614232 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic alliance in psychotherapy
Number of subjects: 0
Study 32614232 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic synchrony between patients and therapists
Number of subjects: 0
Study 35925734 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive program (pediatric goal management training)
Number of subjects: 73
Study 35925734 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational program (pediatric brain health workshop)
Number of subjects: 73
Study 35925734 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 73
Study 33620328 — intervention group
Group type: EXPERIMENTAL
Intervention: Program B (fixed order CBT-based stress management)
Number of subjects: 949
Study 33620328 — intervention group
Group type: EXPERIMENTAL
Intervention: Program A (free-choice CBT-based stress management)
Number of subjects: 949
Study 33620328 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 949
Study 33108935 — intervention group
Group type: EXPERIMENTAL
Intervention: Industry-sponsored trials
Number of subjects: 216
Study 33108935 — intervention group
Group type: COMPARATOR
Intervention: Non-industry trials
Number of subjects: 216
Study 33108935 — intervention group
Group type: EXPERIMENTAL
Intervention: Industry trials
Number of subjects: 216
Study 35296626 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% without benzalkonium chloride (BAK)
Number of subjects: 578
Study 35296626 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005% with benzalkonium chloride (BAK)
Number of subjects: 578
Study 32291094 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard doses thromboprophylaxis
Number of subjects: 184
Study 36267027 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber supplementation (19.56 g day‐1)
Number of subjects: 100
Study 36267027 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard prenatal care)
Number of subjects: 100
Study 33618051 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval exercise (IE) - 30 min at 100% peak work capacity (WRpeak) for 30s alternated with 40% WRpeak for 30s, 3 times weekly for 12 weeks
Number of subjects: 24
Study 33618051 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval exercise (IE)
Number of subjects: 24
Study 33618051 — intervention group
Group type: COMPARATOR
Intervention: Constant-load exercise (CLE) - 30 min at 70% WRpeak, 3 times weekly for 12 weeks
Number of subjects: 24
Study 33618051 — intervention group
Group type: COMPARATOR
Intervention: Constant-load exercise (CLE)
Number of subjects: 24
Study 36093101 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for cumulative live birth (CLB) prediction
Number of subjects: 26689
Study 34009282 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy (CBT) for 12 weeks (n = 51)
Number of subjects: 102
Study 34009282 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n = 51)
Number of subjects: 102
Study 32386068 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncultured epidermal cell suspension (NCES)
Number of subjects: 30
Study 32386068 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction blister epidermal grafting (SBEG)
Number of subjects: 30
Study 32386068 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini punch grafting (MPG)
Number of subjects: 30
Study 32386068 — intervention group
Group type: EXPERIMENTAL
Intervention: Color matching and patient satisfaction
Number of subjects: 30
Study 32386068 — intervention group
Group type: COMPARATOR
Intervention: Comparison between NCES and MPG, SBEG and MPG
Number of subjects: 30
Study 36328040 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab plus lenalidomide, bortezomib, and dexamethasone
Number of subjects: 660
Study 36328040 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide, bortezomib, and dexamethasone (control group)
Number of subjects: 660
Study 33560426 — intervention group
Group type: EXPERIMENTAL
Intervention: AppyCDS intervention
Number of subjects: 5938
Study 34416295 — intervention group
Group type: EXPERIMENTAL
Intervention: Detoxifying and blood-activating Chinese medicine granules (15 g of Polygonum cuspidatum and 10 g of Crataegus pinnatifida for 4 weeks)
Number of subjects: 144
Study 34416295 — intervention group
Group type: COMPARATOR
Intervention: Standardized Western medicine (control group)
Number of subjects: 144
Study 32370760 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased non-alcoholic drinks (six non-alcoholic, two alcoholic drinks)
Number of subjects: 808
Study 32370760 — intervention group
Group type: COMPARATOR
Intervention: Reference 1 (two non-alcoholic, two alcoholic drinks)
Number of subjects: 808
Study 32370760 — intervention group
Group type: COMPARATOR
Intervention: Reference 2 (four non-alcoholic, four alcoholic drinks)
Number of subjects: 808
Study 32370760 — intervention group
Group type: COMPARATOR
Intervention: Increased alcoholic drinks (two non-alcoholic, six alcoholic drinks)
Number of subjects: 808
Study 32370760 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference 1 to Increased non-alcoholic drinks condition
Number of subjects: 808
Study 32370760 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference 2 to Increased non-alcoholic drinks condition
Number of subjects: 808
Study 35648209 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombined Contrast-Enhanced Mammography (rCEM)
Number of subjects: 220
Study 35648209 — intervention group
Group type: COMPARATOR
Intervention: Standard Assessment (SA)
Number of subjects: 220
Study 34210325 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal samples
Number of subjects: 100
Study 34210325 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood samples
Number of subjects: 100
Study 34210325 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine samples
Number of subjects: 100
Study 34210325 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool samples
Number of subjects: 100
Study 33074557 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly semaglutide 0.5 mg
Number of subjects: 868
Study 33074557 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly semaglutide 1.0 mg
Number of subjects: 868
Study 33074557 — intervention group
Group type: COMPARATOR
Intervention: Once-daily sitagliptin 100 mg
Number of subjects: 868
Study 33074557 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of semaglutide
Number of subjects: 868
Study 33888407 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunlight exposure (5 days a week for 4 weeks, average duration 21 ± 5 minutes)
Number of subjects: 40
Study 33888407 — intervention group
Group type: COMPARATOR
Intervention: No sunlight exposure (control group)
Number of subjects: 40
Study 33888407 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunlight exposure
Number of subjects: 40
Study 33314690 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) ablation
Number of subjects: 194
Study 33730209 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5K1:5P
Number of subjects: 10
Study 33730209 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5K1:5P
Number of subjects: 10
Study 33730209 — intervention group
Group type: COMPARATOR
Intervention: 3.5K1:5P
Number of subjects: 10
Study 33730209 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5K1:4P
Number of subjects: 10
Study 33730209 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5K1:3P
Number of subjects: 10
Study 33730209 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5K1:5A
Number of subjects: 10
Study 32703769 — intervention group
Group type: EXPERIMENTAL
Intervention: Asparaginase
Number of subjects: 0
Study 32703769 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic GSK3α inhibition
Number of subjects: 0
Study 32703769 — intervention group
Group type: COMPARATOR
Intervention: Normal intestinal progenitors
Number of subjects: 0
Study 34269326 — intervention group
Group type: EXPERIMENTAL
Intervention: ZXR00 IOL
Number of subjects: 299
Study 34380638 — intervention group
Group type: EXPERIMENTAL
Intervention: OncoMasTR Risk Score
Number of subjects: 1200
Study 32758231 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental malaria (IFN-β and IL-10 expression) in multigravidas
Number of subjects: 40
Study 32758231 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-β levels in multigravidas with placental malaria
Number of subjects: 40
Study 32758231 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-β levels in general
Number of subjects: 40
Study 32758231 — intervention group
Group type: COMPARATOR
Intervention: Uninfected controls (gravidity-matched)
Number of subjects: 40
Study 33026160 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 2 mg (ExQW)
Number of subjects: 42
Study 33026160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 32341326 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothyroidism group
Number of subjects: 69584
Study 33479111 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-directed prescribing
Number of subjects: 241
Study 33479111 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-directed prescribing (AA genotype)
Number of subjects: 241
Study 33479111 — intervention group
Group type: COMPARATOR
Intervention: Standard guideline care
Number of subjects: 241
Study 32210849 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal speech-gesture training (MSG training), 8 sessions of 60 minutes each.
Number of subjects: 30
Study 32210849 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group, N=20.
Number of subjects: 30
Study 32210849 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls, N=30.
Number of subjects: 30
Study 36229952 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium energy level (energy level 3)
Number of subjects: 20
Study 36229952 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy level (energy level 5)
Number of subjects: 20
Study 33441146 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium/indacaterol (Gly/Ind)
Number of subjects: 75
Study 33441146 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol (Ume/Vil)
Number of subjects: 75
Study 33441146 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium/olodaterol (Tio/Olo)
Number of subjects: 75
Study 32289301 — intervention group
Group type: EXPERIMENTAL
Intervention: Online‐MUF
Number of subjects: 99
Study 32289301 — intervention group
Group type: COMPARATOR
Intervention: Offline‐MUF
Number of subjects: 99
Study 32289301 — intervention group
Group type: COMPARATOR
Intervention: Centrifugation
Number of subjects: 99
Study 35642157 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS) - 1 Hz, 15 min, 5 d/week for 2 weeks
Number of subjects: 26
Study 35642157 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror Therapy (MT) - corresponding movements of limbs, 15 min, 5 d/week for 2 weeks
Number of subjects: 26
Study 35642157 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 26
Study 34151880 — intervention group
Group type: EXPERIMENTAL
Intervention: CESM-based radiomics model using low energy images
Number of subjects: 205
Study 34151880 — intervention group
Group type: EXPERIMENTAL
Intervention: CESM-based radiomics model using subtracted images
Number of subjects: 205
Study 34151880 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model using low energy and subtracted images
Number of subjects: 205